1 – 3 of 3
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2012
-
Mark
Cost-utility analysis of adjuvant therapies for breast cancer in iran
(
- Contribution to journal › Article
- 2011
-
Mark
Health-related quality of life after chemotherapy cycle in breast cancer in Iran
(
- Contribution to journal › Article
-
Mark
Quality of life and toxicity in breast cancer patients using adjuvant TAC (docetaxel, doxorubicin, cyclophosphamide), in comparison with FAC (doxorubicin, cyclophosphamide, 5-fluorouracil).
(
- Contribution to journal › Article